- Home
- TENB vs VRDN Comparison
TENB vs VRDN Comparison
Compare TENB & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TENB | VRDN |
|---|---|---|
| Founded | 2002 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 3.2B |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | TENB | VRDN |
|---|---|---|
| Price | $21.96 | $32.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 13 |
| Target Price | $37.59 | ★ $41.17 |
| AVG Volume (30 Days) | ★ 1.7M | 1.5M |
| Earning Date | 02-04-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $974,603,000.00 | $70,789,000.00 |
| Revenue This Year | $12.22 | $26,080.80 |
| Revenue Next Year | $7.62 | $3.26 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 11.05 | ★ 23340.07 |
| 52 Week Low | $21.26 | $9.90 |
| 52 Week High | $43.84 | $34.29 |
Technical Indicators
Market Signals| Indicator | TENB | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 37.11 | 55.11 |
| Support Level | $21.26 | $31.26 |
| Resistance Level | $23.32 | $34.20 |
| Average True Range (ATR) | 0.64 | 1.36 |
| MACD | 0.05 | 0.03 |
| Stochastic Oscillator | 32.54 | 57.83 |
Price Performance
Historical ComparisonAbout TENB Tenable Holdings Inc.
Founded in 2002, Tenable is a cybersecurity company that began providing vulnerability management solutions under its Nessus software. In recent years, Tenable has expanded its portfolio to provide a broader range of exposure management modules. Solutions include cloud security and compliance, active directory management, operational technology security and advanced vulnerability analytics. The Maryland-based company went public in 2018.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).